Ustekinumab under the trade name Stelara (also known as CNTO 1275) is an immunosuppressant used to treat plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Ustekinumab as the first biologic therapy for Crohn’s disease is the only treatment for Crohn’s disease that starts with a weight-based, one-time intravenous (IV) infusion induction dose.
Sitagliptin previously identified as MK-0431 and marketed as the phosphate salt under the trade name Januvia is an oral Type 2 diabetes medication manufactured by Merck & Co. This new oral hypoglycemic (anti-diabetic) drug is the top-selling brand in its class. In 2007, an oral combination of sitagliptin and metformin was marketed in the US as Janumet.
Aflibercept with the trade name Eylea is made from a human antibody fragment. Regeneron Pharmaceuticals invented this biopharmaceutical drug for the treatment of wet macular degeneration as Eylea injection and also for metastatic colorectal cancer under the trade name Zaltrap.